NANTOMICS AND NANTHEALTH PUBLISHED RECENT RESEARCH IN ONCOTARGET DISCUSSING THE IMPORTANCE OF TUMOR-NORMAL SEQUENCING.   ‡

NANTOMICS AND NANTHEALTH PUBLISHED RECENT RESEARCH IN ONCOTARGET DISCUSSING THE IMPORTANCE OF TUMOR-NORMAL SEQUENCING.   ‡

GPS Cancer is a precise and comprehensive molecular profile, integrating tumor-normal sequencing of DNA (whole genome/exome) with RNA sequencing.

GPS Cancer, run in CLIA-certified CAP-accredited laboratories, provides oncologists with a precise and comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies before treatment begins. GPS Cancer results may inform use of commonly used targeted therapies, chemotherapies, and immunotherapies.

 

Addressing the question:

Doctor, what information do you have from my tumor tissue that will help inform you that the treatment you are about to prescribe has a probability of being effective?

GPS Cancer® report:

  • Includes whole genome or whole exome sequencing of 20,000 genes and 3 billion base pairs
  • Incorporates whole transcriptome sequencing of over 200,000 RNA transcripts
  • Compares a patient’s tumor genome to their normal genome

The GPS Cancer® test results are available to the ordering physician within 21 days (typical) from receipt of tissue in a concise format. The GPS Cancer report lists potential treatment options (if applicable), including FDA-approved targeted therapies and active clinical trials with potential for clinical benefit, and/or available therapies to which the cancer may be resistant. The GPS Cancer report does not recommend treatments, and it is the responsibility of the treating physician to develop a personalized treatment plan after discussing available treatment options and the potential risks associated with each treatment option with the patient.

To learn more about GPS Cancer, contact us at 1-844-MY-OMICS / 1-844-696-6427 or GPSCancer@NantHealth.com


‡ Rabizadeh et al. Comprehensive genomic transcriptomic tumor-normal gene panel analysis for enhanced precision in patients with lung cancer. Oncotarget. 2018; 9:19223-19232. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0).